Connect with us

Hi, what are you looking for?

Artificial Intelligence

MedRhythms Raises $25M to Get Patients Back in Tune After a Stroke

MedRhythms Raises $25M to Get Patients Back in Tune After a Stroke

MedRhythms secured $25 million in Series B funding to advance its digital therapy platform aimed at measuring and improving someone’s ability to walk after they have experienced a neurologic injury or disease.

Morningside Ventures and Advantage Capital co-led the round, with participation from existing investor Werth Family Investment Associates, to give the Portland, Maine-based company $31 million in funding to date.

Company co-founder and CEO Brian Harris was a neurologic music fellow at Spaulding Rehabilitation Hospital in Boston, treating people with stroke and brain deficits with music. He began getting questions from patients and families on how they could access similar care outside of the hospital. Not seeing a suitable alternative, he started MedRhythms with entrepreneur Owen McCarthy in 2016.

The company’s platform uses sensors, music and software, along with an evidence-based intervention called “rhythmic auditory stimulation,” to target the neural circuitry that controls movement. The technology taps into “entrainment,” a neurologic process in which the auditory and motor systems of the brain are coupled in synchrony with an external rhythmic cue, which over time, can lead to improved walking functionalities.

“There is no other stimulus that engages the brain like music does,” Harris said. “When someone is engaging in music, it aids in neuroplasticity to create new connections and strengthen old ones. Neuroplasticity is how we can learn new things or why people with brain deficits can improve.”

A year ago, MedRhythms’ digital therapeutic product received Breakthrough Device designation from the U.S. Food and Drug Administration to treat chronic walking deficits resulting from a stroke. It is the first in the company’s pipeline, which is also looking at using music to treat neurological conditions like Parkinson’s, acute stroke and multiple sclerosis. To that effect, it is participating in a neuroimaging study with Massachusetts General Hospital.

Harris intends to use the proceeds from the Series B funding to get the product to market, expand the team and the treatment pipeline. The company is preparing for submission to the FDA so it can do a commercial launch of the technology and begin clinical trials.

Stephen Bruso, investment partner at Morningside, said he has known the team at MedRhythms for a year. The firm is active in the digital health space and has followed the company closely since then.

COVID served to fundamentally shift healthcare in how to deliver care. The hospital and clinic models were robust, but resistant to change until the pandemic forced care to telemedicine visits at home, he said. It also forced innovation on the industry, and at-home therapy is an area where Bruso expects to see improvement in both patient compliance and recovery, and MedRhythms is capitalizing on that trend of shifting care to the home.

What intrigued the firm for the last couple of months was the idea of affecting the brain via non-pharmaceutical needs.

“MedRhythms using musical intervention to drive changes and improvements in neurologics is compelling,” Bruso added. “Emotional memory is tied to music. Its use provides a richer experience than taking a drug, and the company exists to tap into that.”

Seen on TechCrunch: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

COVID-19

Dr Ishara Dharmasena, of the School of Mechanical, Electrical and Manufacturing Engineering (MEME), has been appointed a research fellow by the Royal Academy of Engineering and awarded funding...

COVID-19

Evidence of the impact on medtech emerged over the summer, when ResMed cited the shortage of semiconductors as a reason it will be unable...

Consumer Empowered Health

Meru Health is a startup that aims to solve a number of the challenges associated with getting access to quality mental health care, with...

BioTechnology

The NHS has launched the world’s largest trial for a blood test that can detect 50 types of cancer before symptoms appear.

You May Also Like

Artificial Intelligence

Digital Solutions In Healthcare Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm....

COVID-19

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Artificial Intelligence

Joe Mullings discusses the Microbot – Liberty robotic platform with Harel Gadot and how a new category of surgical robotics creates a new entry...

Digital Health

Software as a Medical Device (SaMD) is driving innovation in the HealthTech space and is more popular than ever — completely upending the way...